Hépato-Gastro & Oncologie Digestive
MENUHepatitis B virus reactivation in patients with digestive tract tumours receiving systemic anti-cancer treatment Volume 24, issue 7, Septembre 2017
Tables
- Key words: chemotherapy, solid tumors, hepatitis B virus, reactivation of hepatitis B
- DOI : 10.1684/hpg.2017.1483
- Page(s) : 689-96
- Published in: 2017
Patients treated with chemotherapy for haematological disease have a known risk of reactivation of hepatitis B virus (HBV) with an estimated incidence of 14-72%. Conversely, very little data exist on viral B reactivation in patients receiving chemotherapy for a digestive malignancy.
In this review, a search of the literature data was carried out in an attempt to evaluate the risk of reactivation of HBV during treatment for a digestive malignancy. Based on these data, a ranking of the risk of HBV reactivation and recommendations for the most commonly used anticancer drugs in solid tumors was performed.
The majority of anti-cancer drugs can in patients with HBs-positive antigen induce reactivation of HBV. Screening for HBs antigen should be recommended before chemotherapy. Thus, preventive antiviral therapy can therefore reduce the risk of reactivation of HBV.